17 completed, 4 unknown, 2 active not recruiting, 2 recruiting. 11 Not applicable, 4 Phase 2, 4 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 11 | Completed 6, Active not recruiting 2, Unknown 2, Recruiting 1 |
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 3 | 4 | Completed 4 |
| Phase 4 | 2 | Completed 2 |
Follow Dementia, Alzheimer Type: new trials by email Literature Review of Dementia, Alzheimer Type trials Research Report on Dementia, Alzheimer Type
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease Dementia, Alzheimer Type, Mild Cognitive Impairment | Recruiting | University Hospital, Essen | 15 | 2022-08-15 | 2025-09-04 | |
| Association of Cognition With Functional Mobility in People With Alzheimer's Disease Alzheimer Dementia, Alzheimer's Disease | Unknown | Istanbul University - Cerrahpasa | 64 | 2021-11-01 | 2021-11-09 | |
| Deep Brain Stimulation for Alzheimer's Disease Deep brain stimulation, Best medical treatment for Alzheimer's disease - Alzheimer Disease, Dementia, Alzheimer Type | Not applicable | Unknown | Buddhist Tzu Chi General Hospital | 30 | 2020-04-06 | 2020-07-17 |
| Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE) ABC Clinical Program, BCN - Dementia, Alzheimer Type | Not applicable | Completed | Indiana University | 53 | 2019-11-25 | 2024-09-19 |
| Intervention of Intestinal Microorganism in Mild Cognitive Impairment Probiotic supplemented intervention, Placebo - Gut Microbiota, Mild Cognitive Impairment | Not applicable | Completed | XuanwuH 2 | 90 | 2019-08-31 | 2022-07-13 |
| Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)" Physical activity, Successful Aging - Dementia, Alzheimer Type | Not applicable | Recruiting | Pennington Biomedical Research Center | 125 | 2019-08-09 | 2024-11-25 |
| Targeting Brain Physiology to Treat Neuropsychiatric Symptoms of Dementia Using TMS-EEG and tDCS Transcranial Direct Current Stimulation (tDCS) - Alzheimer Disease, Dementia, Mixed | Not applicable | Active not recruiting | Centre for Addiction and Mental Health | 90 | 2019-04-24 | 2026-04-13 |
| Movement Intervention for Memory Enhancement Social Dancing, Treadmill Walking - Alzheimer Disease, Dementia | Not applicable | Completed | Albert Einstein College of Medicine | 25 | 2019-03-28 | 2021-08-16 |
| Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type Renew NCP-5 - Alzheimer Disease, Cognitive Dysfunction | Phase 3 | Completed | Renew Research, LLC | 190 | 2018-11-12 | 2022-05-11 |
| Studies of Brain and Body Interaction Autistic Disorders Spectrum, Adhd | Completed | Rutgers University | 30 | 2018-08-01 | 2026-04-29 | |
| Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study) GammaSense Stimulation System (non-invasive, non-significant risk) - Alzheimer Disease, Early Onset, Alzheimer Disease | Not applicable | Unknown | Cognito Therapeutics, Inc. | 20 | 2018-05-31 | 2021-08-24 |
| Multi-Center Study of Sensory Stimulation to Improve Brain Function GammaSense Stimulation System (Active Settings), GammaSense Stimulation System (Sham Settings) - Alzheimer Disease, Cognitive Impairment | Not applicable | Active not recruiting | Cognito Therapeutics, Inc. | 60 | 2018-04-24 | 2021-08-24 |
| Partners at Meals - Respite Care and Home (PAM) Partners at Meals, Enhanced Usual Condition - Dementia, Alzheimer Type, Weight Loss | Not applicable | Completed | Medical University of South Carolina | 106 | 2017-08-15 | 2025-04-10 |
| Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia) Vielight Neuro Gamma - Dementia, Alzheimer Type | Not applicable | Completed | University of California, San Francisco | 20 | 2017-05-15 | 2020-10-06 |
| A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) Xanamem™, Placebo (for Xanamem™) - Dementia, Alzheimer Type | Phase 2 | Completed | Actinogen Medical | 185 | 2017-03-23 | 2025-02-03 |
| Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA) MoCA - Cognitive Impairment, Cognitive Decline | Completed | Andreas Monsch | 334 | 2016-12-01 | 2018-05-31 | |
| Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks Alzheimer Disease, Early Onset, Alzheimer Disease | Completed | University of California, Los Angeles | 180 | 2016-04-04 | 2025-04-30 | |
| Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease E2609, Placebo - Alzheimer Disease, Dementia, Alzheimer Type | Phase 2 | Terminated | Eisai Inc. | 70 | 2014-11-26 | 2021-03-05 |
| Home Evaluation of Exit Barriers in Wandering Door cover/Floor cover - Dementia, Alzheimer Type, Problem Behavior | Not applicable | Completed | US Department of Veterans Affairs | 19 | 2009-10-01 | 2014-11-21 |
| Memantine Versus Donepezil in Early Stages of Alzheimer's Disease Memantine, Donepezil - Dementia, Alzheimer Type | Phase 4 | Completed | Hospital Miguel Servet | 64 | 2007-07-01 | 2008-12-29 |
Showing 20 of 26. Sign in to see all of them.
Alzheimer Disease (26) · Dementia (10) · Cognitive Dysfunction (9) · Lymphoma, Follicular (3) · Mental Disorders (2) · Psychomotor Agitation (2) · Aberrant Motor Behavior in Dementia (1) · Amyloid Neuropathies, Familial (1) · Aphasia, Primary Progressive (1) · Apraxia, Ideomotor (1) · Apraxias (1) · Asperger Syndrome (1) · Attention Deficit Disorder with Hyperactivity (1) · Child Development Disorders, Pervasive (1) · Cognition Disorders (1)
Brain Diseases (26) · Central Nervous System Diseases (26) · Nervous System Diseases (26) · Neurocognitive Disorders (26) · Neurodegenerative Diseases (26) · Tauopathies (26) · Mental Disorders (24) · Dementia (16) · Cognition Disorders (8) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Behavior (5) · Neurologic Manifestations (5) · Neurobehavioral Manifestations (4) · Behavioral Symptoms (3)
Memantine (2) · Amyloid beta-Protein Precursor (1) · Aripiprazole (1) · Deep Brain Stimulation (1) · Donepezil (1) · Exercise (1) · Olanzapine (1) · Quetiapine Fumarate (1) · Risperidone (1) · Rivastigmine (1) · Transcranial Direct Current Stimulation (1) · UE2343 (1) · Valproic Acid (1)
Cognito Therapeutics, Inc. (2) · Actinogen Medical (1) · Albert Einstein College of Medicine (1) · Andreas Monsch (1) · Buddhist Tzu Chi General Hospital (1) · Centre for Addiction and Mental Health (1) · Eisai Inc. (1) · Emory University (1) · Hospital Miguel Servet (1) · Indiana University (1) · Istanbul University - Cerrahpasa (1) · Medical University of South Carolina (1) · National Taiwan University Hospital (1) · Novartis Pharmaceuticals (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1)
United States (16) · Taiwan (3) · Germany (2) · Australia (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · Denmark (1) · Finland (1) · Guatemala (1) · Ireland (1) · Israel (1) · Italy (1) · Mexico (1)
Alan Boyd, MD, FFPM (1) · Alessandra Thomann, MSc (1) · Andreas Monsch, PhD (1) · Bill Ketelbey, MD (1) · Billy Tally (1) · Claude M Wischik, MBChB (1) · Dorothy H Moore, PhD MA BSW (1) · Evan R Hempel (1) · Helena Blumen, PhD (1) · Joe Verghese, MBBS (1) · Larry E. Tune, MD, MAS (1) · Laura N Gitlin, Ph.D (1) · Linda L Chao, PhD (1) · Malaz Boustani, MD, MPH (1)
PMID 19874395, PMID 20810376, PMID 20921879, PMID 21312297, PMID 25550228, PMID 27681702, PMID 33431027, PMID 34630050, PMID 38515445, PMID 38848180, PMID 40082316
1RF1AG050967-01A1 (1), 2014 (1), R01AG062200 (1), R21AG057586 (1), R21AG062966 (1)